澳大利亚全国疫苗接种项目实施八年后,年轻女性生殖道人乳头瘤病毒基因型流行率研究的最终分析
VACCINE研究评估了澳大利亚维多利亚州18-25岁疫苗适龄女性中四价疫苗靶向HPV基因型(6、11、16、18型)的流行率。2011年10月至2015年6月通过Facebook招募,参与者完成在线问卷并提供自采阴道拭子进行HPV DNA检测和基因分型,疫苗接种信息经国家HPV疫苗接种登记处核实。结果显示疫苗靶向HPV基因型仅检出13例(1.7%),HPV 31/33/45合并流行率为2.9%,且随疫苗接种状态显著变化(完全接种2.0% vs 未接种6.8%;p=0.01)。
要点
- 疫苗靶向HPV基因型在737名有可检测DNA的女性中仅13例(1.7%)检出。
- HPV 31/33/45合并流行率完全接种者2.0% vs 未接种者6.8%(p=0.01)。
- 性活跃队列中三剂、至少两剂、至少一剂疫苗接种率分别为65.6%、71.6%、74.2%。
核心结论
- 全国HPV疫苗接种项目实施五至八年后监测显示,澳大利亚维多利亚州疫苗适龄女性中疫苗相关HPV基因型流行率持续且非常低,并有一些针对相关型别交叉保护的证据。
研究设计与样本
- VACCINE(Vaccine Against Cervical Cancer Impact and Effectiveness)研究,2011年10月至2015年6月通过社交网站Facebook定向广告招募澳大利亚维多利亚州18-25岁女性,参与者完成在线问卷并提供自采阴道拭子进行HPV DNA检测和基因分型(Linear Array HPV基因分型检测),自报疫苗接种信息经国家HPV疫苗接种登记处(NHVPR)核实。
主要发现
- 1223人同意参与,916人(74.9%)完成调查;1007名性活跃参与者中744人(73.9%)交回自采拭子,其中737份含可检测DNA;184/737(25.0%)HPV阳性。
- 疫苗靶向HPV基因型仅在13名女性(1.7%)中检出:11例HPV 16(6例首次性行为后接种,5例未接种)和2例HPV 6。
- HPV 31/33/45合并流行率为2.9%,随疫苗接种状态显著变化:完全接种2.0% vs 未接种6.8%(p=0.01)。
- 性活跃队列中三剂、至少两剂、至少一剂疫苗接种率分别为65.6%、71.6%、74.2%;自报接种者中NHVPR确认至少一剂接种的比例为90%。
- 疫苗接种状态与年龄、家庭语言、出生国之间存在强关联,HPV检出与男性性伴侣数量之间也存在强关联。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The VACCINE [Vaccine Against Cervical Cancer Impact and Effectiveness] study evaluated the prevalence of quadrivalent vaccine-targeted human papillomavirus (HPV) genotypes (HPV 6, 11, 16, 18) amongst young women of vaccine-eligible age. METHODS: Between October 2011 - June 2015, women aged 18-25 years from Victoria, Australia, were recruited through targeted advertising on the social networking website Facebook. Participants completed an online questionnaire and provided a self-collected vaginal swab for HPV DNA detection and genotyping (Linear Array HPV genotyping assay). Self-reported HPV vaccination details were verified with the National HPV Vaccination Program Register (NHVPR). RESULTS: Of 1223 who agreed to participate, 916 (74.9%) completed the survey and, for 1007 (82.3%) sexually-active participants, 744 (73.9%) returned the self-collected swab, of which 737 contained detectable DNA. 184/737 (25.0%) were positive for HPV. Vaccine-targeted HPV genotypes were detected in only 13 (1.7%) women: 11 HPV 16 (six vaccinated after sexual debut, five unvaccinated) and two HPV 6. Prevalence of any of HPV 31/33/45 collectively was 2.9%, varying significantly by vaccination status (fully 2.0%, unvaccinated 6.8%; p = 0.01). Vaccination rates among the sexually-active cohort were high, with 65.6%, 71.6% and 74.2% of participants having received three, at least two or at least one dose of vaccine, respectively. Of women self-reporting HPV vaccination, the NHVPR confirmed one or more doses were received in 90%. Strong associations were observed between vaccination status, age, language spoken at home and country of birth, as well as between HPV detection and the number of male sexual partners. CONCLUSION: Surveillance five to eight years' post-initiation of a national HPV vaccination program demonstrated a consistent and very low prevalence of vaccine-related HPV genotypes and some evidence of cross protection against related types amongst vaccine-eligible women from Victoria, Australia.
引用
- Garland SM, Cornall AM, Brotherton JML, et al. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program. Vaccine. 2018. PMID: 29724506. doi:10.1016/j.vaccine.2018.04.080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。